BUDESHINE 100 INH: Low-Dose Budesonide Inhaler for Mild Asthma Control

 BUDESHINE 100 INH, manufactured by Steris Healthcare, contains Budesonide I.P. 100 mcg, an inhaled corticosteroid delivered via a metered-dose or dry powder inhaler device for the regular maintenance treatment of mild bronchial asthma. This lower strength is typically prescribed for patients with mild persistent asthma, those newly starting inhaled corticosteroid therapy, pediatric patients requiring a gentler introductory dose, or as a step-down option for patients whose asthma has become well controlled on a higher strength. Like all inhaled corticosteroids, BUDESHINE 100 INH targets the chronic underlying airway inflammation rather than providing immediate symptom relief, making it a foundational maintenance therapy rather than a rescue medication.

Why It's Important

Many patients with mild persistent asthma either go untreated with anti-inflammatory therapy altogether — relying only on rescue bronchodilators during flare-ups — or are started on unnecessarily high corticosteroid doses that increase the risk of local and systemic side effects without added clinical benefit. Appropriate dose-matching is a core principle of asthma management: using the lowest effective inhaled corticosteroid dose that achieves good symptom control minimizes side effect risk while still protecting against the silent, ongoing airway inflammation that drives long-term disease progression. BUDESHINE 100 INH fills this important role, offering a low-dose starting point or maintenance option for patients whose asthma severity does not require higher-strength therapy, supporting a more individualized, guideline-based approach to treatment.

Key Benefits 

What are the benefits?

• Effective anti-inflammatory control for mild persistent asthma
• Suitable low-dose starting option for new inhaled corticosteroid users
• Gentle strength appropriate for pediatric maintenance therapy
• Useful step-down option once asthma is well controlled
• Manufactured under WHO-GMP and ISO 9001:2018 certified facility standards by Steris Healthcare, ensuring consistent potency and quality

Side Effects

Common side effects may include mild throat irritation, hoarseness of voice, dry cough, or headache, with oral thrush occurring occasionally if the mouth is not rinsed after use.

Serious Side Effects 

Seek immediate medical attention for signs of a severe allergic reaction such as facial swelling or difficulty breathing, worsening breathlessness immediately after use, or, with prolonged use, signs of adrenal suppression such as unusual fatigue or low blood pressure. Growth should be periodically monitored in children on long-term therapy.

Available Substitute 

Several branded budesonide inhalation formulations are available in the Indian market at comparable low strengths and delivery devices. Brand or device switches should only be made under physician guidance, as inhaler technique and design can affect drug delivery consistency.

Dosage Guidelines 

Dosage is individualized by the treating physician based on asthma severity and patient response, typically one to two inhalations twice daily. Patients should be trained on correct inhaler technique for effective lung deposition and should rinse the mouth with water after each use to minimize local side effects. Missed doses should not be doubled.

Precautions & Warnings

Use cautiously in patients with active or latent pulmonary tuberculosis, respiratory tract infections, or ocular herpes simplex due to the localized immunosuppressive effect of inhaled corticosteroids. It should not be used as a rescue medication during acute bronchospasm. Avoid abrupt discontinuation; taper gradually under physician guidance.

Mechanism of Action

Budesonide binds to intracellular glucocorticoid receptors in airway cells, modulating gene transcription to suppress pro-inflammatory mediators and reduce recruitment of inflammatory cells such as eosinophils and mast cells. This reduces airway mucosal edema, mucus hypersecretion, and hyperresponsiveness, addressing the chronic inflammatory basis of asthma even at this lower dose strength.

Conclusion

BUDESHINE 100 INH by Steris Healthcare offers a well-matched, low-dose inhaled corticosteroid option for mild persistent asthma and pediatric or step-down maintenance therapy. Consistent use under physician guidance supports stable long-term symptom control while minimizing unnecessary corticosteroid exposure.